LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Levaquin In Dextrose 5% In Plastic Container, and when can generic versions of Levaquin In Dextrose 5% In Plastic Container launch?

Levaquin In Dextrose 5% In Plastic Container is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levaquin In Dextrose 5% In Plastic Container

A generic version of LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as levofloxacin by RISING on December 20^th, 2010.

Summary for LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	24
DailyMed Link:	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Indonesia University	Phase 1/Phase 2
Harvard Medical School (HMS and HSDM)	Phase 2
University of Colorado, Denver	Phase 2

See all LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	020635-002	Dec 20, 1996		DISCN	Yes	No
Janssen Pharms	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	020635-003	Dec 20, 1996		DISCN	Yes	No
Janssen Pharms	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	020635-005	Dec 20, 1996		DISCN	Yes	No

Expired US Patents for LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	020635-005	Dec 20, 1996
Janssen Pharms	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	020635-002	Dec 20, 1996
Janssen Pharms	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	020635-003	Dec 20, 1996
Janssen Pharms	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	020635-003	Dec 20, 1996

EU/EMA Drug Approvals for LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Chiesi Farmaceutici S.p.A	Quinsair	levofloxacin	EMEA/H/C/002789Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2015-03-25

International Patents for LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

See the table below for patents covering LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	862643
Finland	71155
Ireland	930628
Japan	S5746986	PYRIDO(1,2,3-DE)(1,4)BENZOXAZINE DERIVATIVE

Supplementary Protection Certificates for LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0206283	SPC/GB97/085	United Kingdom		PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606
0206283	98C0041	Belgium		PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
0206283	C980016	Netherlands		PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606

Market Dynamics and Financial Trajectory for LEVAQUIN in Dextrose 5% in Plastic Container

Last updated: July 28, 2025

---

Introduction

Levaquin (levofloxacin), a broad-spectrum fluoroquinolone antibiotic, remains a pivotal option in combating various bacterial infections. Its formulation in dextrose 5% in a plastic container (D5W) aligns with clinical preferences for intravenous therapy, especially in hospital and institutional settings. This analysis explores the market dynamics, competitive landscape, regulatory environment, and financial trajectory of Levaquin in D5W plastic containers, aiming to inform strategic decision-making within pharmaceutical and healthcare sectors.

---

Market Overview

Product Profile and Usage

Levaquin in Dextrose 5% (D5W) infusion form targets IV administration, primarily for hospitalized patients requiring systemic bacterial infection treatment. Its stability, compatibility, and ease of administration in plastic containers position it as a standard in IV therapy protocols. The formulation's convenience supports infection management across diverse clinical settings—from acute care to outpatient intravenous therapies.

Market Demand Drivers

• Rising Hospitalization Rates: Increased incidences of bacterial infections, including pneumonia, urinary tract infections, and skin infections, elevate demand for IV antibiotics like Levaquin.
• Antibiotic Stewardship Programs: Growing emphasis on optimizing antimicrobial use drives demand for potent, broad-spectrum agents with proven efficacy.
• Patient Preference for Outpatient Care: The shift toward outpatient IV therapies and outpatient infusion centers propels demand for stable, ready-to-administer formulations.
• Preference for Plastic Containers: Advantages include lightweight design, reduced breakage risk, and compatibility with infusion systems, increasing the popularity of plastic container formulations.

---

Competitive Landscape

Key Players

• Janssen Pharmaceuticals: Original developer of Levaquin, holding significant market share.
• Generic Pharmaceutical Manufacturers: Multiple firms produce generic equivalents, intensifying price competition.
• Alternative IV Antibiotics: Agents like ciprofloxacin, moxifloxacin, and meropenem compete for similar indications.

Market Entry Barriers and Differentiators

• Regulatory Approvals: Stringent approval processes limit new entrants.
• Manufacturing Precision: Strict controls on stability and compatibility, especially in plastic, are essential.
• Brand Loyalty & Clinical Evidence: Strong clinical data and brand recognition support market retention for Janssen's Levaquin.

Innovation and Pipeline Developments

Limited recent innovations suggest the market primarily evolves through generic proliferation, with incremental improvements in packaging or stability profiles.

---

Regulatory Environment

Regulatory Approvals and Contentment

• FDA & EMA Approvals: Require rigorous demonstration of stability, compatibility, and safety, particularly for plastic container formulations.
• Stability Data: Critical for approval, influencing formulation shelf-life and storage conditions.

Impact of Regulations on Market Dynamics

Stringent regulations act as a barrier to entry, favoring established brands with proven safety and stability profiles, thus reinforcing market dominance by Janssen and approved generics.

---

Financial Trajectory Analysis

Revenue Trends

• Historical Revenue Performance: Levaquin's revenues have experienced gradual decline post-patent expiration, correlated with generic entries.
• Recent Market Trends: While total antibiotic sales face pressures from antimicrobial stewardship, specific formulations like Levaquin D5W remain in steady demand within hospital settings.

Pricing Dynamics

• Price Erosion: Increased generic competition has driven down prices substantially; however, premium pricing persists in institutional procurement due to formulation stability and brand trust.
• Market Segmentation: Hospitals tend toward bulk purchasing agreements, offering price discounts but maintaining volume-based revenues.

Profitability and Cost Factors

• Manufacturing Costs: Investment in sterile, high-quality manufacturing, especially for plastic containers, sustains profit margins.
• Regulatory Compliance Expenses: Continual compliance costs affect overall profitability but are critical for market sustainability.

Forecasting Financial Outlook

• Short-term (1-3 years): Slight decline in revenues due to generics, stabilized by institutional demand and limited competition in IV formulations.
• Medium to Long-term (3-10 years): Market stabilization, with potential modest growth driven by new healthcare protocols or formulations, pending regulatory support and clinical adoption.

---

Market Challenges and Opportunities

Challenges

• Generic Competition: Leads to significant pressure on pricing and revenue margins.
• Antimicrobial Resistance: Decreases overall efficacy, potentially limiting the clinical utility of certain antibiotics.
• Regulatory Pressures: Can delay new formulations or renewals affecting market continuity.

Opportunities

• Formulation Innovations: Developing sustained-release versions or improved stability in plastic containers.
• Expanded Indications: Investigating new clinical applications can open additional revenue streams.
• Emerging Markets: Expansion into developing countries offers growth opportunities amid rising infection rates and expanding healthcare infrastructure.

---

Strategic Implications

For stakeholders, maintaining profitability entails a focus on operational efficiencies, leveraging existing infrastructure for cost-effective manufacturing, and pursuing strategic partnerships for market penetration in emerging economies. Robust clinical evidence supporting the efficacy and safety of the D5W formulation can reinforce prescriber trust and differential advantage in competitive hospital formularies.

---

Key Takeaways

• Stable Demand in Institutional Settings: Despite generic competition, Levaquin in D5W containers remains relevant due to clinical efficacy, compatibility with hospital IV protocols, and institutional procurement practices.
• Competitive Pricing Strategy Essential: Managing price erosion requires strategic negotiations with healthcare providers and bulk purchasing agreements.
• Regulatory and Manufacturing Excellence: Compliance with stringent standards sustains market access and profitability.
• Innovation as a Differentiator: Incremental formulation improvements or expanded indications can buffer against declining revenues.
• Emerging Market Penetration: Focused expansion efforts can offset saturation in developed markets.

---

FAQs

1. How does patent expiry influence the market for Levaquin in D5W containers?
Patent expiration has allowed generic manufacturers to enter the market, increasing competition and driving down prices, which affects revenue margins for the original brand. However, stable hospital procurement and clinical preference for the branded formulation can mitigate revenue loss.

2. What are the primary factors influencing the stability of Levaquin in plastic containers?
Key factors include chemical stability of levofloxacin in Dextrose 5%, container material compatibility, and storage conditions. Regulatory authorities require extensive stability data to ensure efficacy throughout the shelf life.

3. How does the trend towards outpatient infusion impact the market for Levaquin D5W formulations?
The shift promotes demand for ready-to-use IV solutions compatible with outpatient settings. Stable, pre-packaged plastic containers suitable for portability and ease of administration are advantageous, supporting market stability.

4. Are there risks associated with manufacturers relying heavily on plastic container formulations?
Yes. Material compatibility issues, regulatory scrutiny over plastic additives, and environmental concerns related to plastic waste could impact manufacturing and market acceptance.

5. What future developments could influence the financial trajectory of Levaquin D5W formulations?
Potential innovations include improved stability, alternative packaging, or new clinical applications. Additionally, evolving regulatory standards or shifts in antimicrobial resistance patterns could markedly influence its economic profile.

---

Sources:
[1] U.S. Food and Drug Administration. Levaquin (levofloxacin) Prescribing Information. 2022.
[2] IQVIA. Global Antibiotics Market Analysis. 2022.
[3] FDA Stability Data for Fluoroquinolone IV Formulations. 2021.
[4] MarketsandMarkets. Antibiotic Market Forecast. 2023.